Astrazeneca (AZN) Amortization (2009 - 2026)

Astrazeneca's Amortization history runs 18 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• In Q1 2026, Amortization fell 40.83% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $12.6 billion (up 11.25% YoY), while the FY2025 annual figure was $85.4 billion, up 9.13% from the prior year.
• Amortization was $3.1 billion for Q1 2026 at Astrazeneca, up from $2.8 billion in the prior quarter.
• In the past five years, Amortization ranged from a high of $84.5 billion in Q3 2025 to a low of $1.4 billion in Q3 2023.
• Historically, Amortization has averaged $35.5 billion across 5 years, with a median of $5.2 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Amortization surged 6189.91% in 2022, then sank 98.14% in 2023.
• A 5-year view of Amortization shows it stood at $1.7 billion in 2022, then rose by 3.91% to $1.8 billion in 2023, then dropped by 15.73% to $1.5 billion in 2024, then surged by 85.27% to $2.8 billion in 2025, then increased by 10.87% to $3.1 billion in 2026.
• The last three Amortization figures came in at $3.1 billion (Q1 2026), $2.8 billion (Q4 2025), and $84.5 billion (Q3 2025), per Business Quant data.